ORYZON to Provide Corporate Progress Updates at Several Events in March-April
Van Lanschot Kempen Life Sciences Conference MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage ...
C4 Therapeutics: Getting Too Cheap To Ignore, But There's Still A Lot Of Risk Here
C4 Therapeutics shows promise in protein degraders but faces safety concerns and long timelines. Click here to find out why I ...
Targeted Oncology5d
Advancing Treatments for ET and CDK4/6 Resistance in HR+ Breast Cancer
New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.
The Manila Times6d
BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
The full audited consolidated financial statements as of and for the year ended December 31, 2024, can be found in BioNTech's Annual Report on Form 20-F filed today with the United States Securities ...
Labroots5d
Immuno-Oncology Virtual Event Series 2025
Labroots is pleased to announce the 4th annual event in the Immuno-Oncology Virtual Event Series taking place on April 30th, 2025. Immuno-Oncology is at the forefront of groundbreaking research in ...